RS

RespireRx Pharmaceuticals IncOOTC RSPI Stock Report

Last reporting period 30 Sep, 2023

Updated 22 Nov, 2024

Last price

Market cap $B

0

Micro

Exchange

OOTC - OTC

RSPI Stock Analysis

RS

Uncovered

RespireRx Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0

Dividend yield

Shares outstanding

119.59 B

RespireRx Pharmaceuticals, Inc. engages in the discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders. The company is headquartered in Glen Rock, New Jersey. The firm is developing treatment options that address obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD) epilepsy, chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect people. The company is developing a pipeline of new and re-purposed drug products based on its patent portfolios for two drug platforms: pharmaceutical cannabinoids platform, is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol, an endocannabinoid CB1 and CB2 receptor agonist, for the treatment of obstructive sleep apnea (OSA) and neuromodulators platform includes AMPAkines that are positive allosteric modulators (PAMs) of AMPA-type glutamate receptors and GABAkines that are PAMs of GABAA receptors.

View Section: Eyestock Rating